Highly rated in
Highly rated in
Check Dr. Scott S. Williams' experience treating your condition:
About Dr. Scott S. Williams

Scott Williams is a Radiation Oncologist in Norfolk, Virginia. Williams has been practicing medicine for over 26 years and is highly rated in 25 conditions, according to our data. His top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Lung Cancer, Pleuropulmonary Blastoma, and Posterior Fossa Tumor. He is licensed to treat patients in Virginia. Williams is currently accepting new patients.

His participating in 4 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Scott S. Williams it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Scott S. Williams accepts the following insurance:

  •  Ambetter
  •  HealthKeepers
  •  Optima Health

Call to see if your plan is accepted.
600 Gresham Dr, Norfolk, VA 23507
Background & Education
Graduate Institution
State University Of New York At Stony Brook, School Of Medicine, 1996
Radiation Oncology
Radiology in VA
Hospital Affiliations
Sentara Obici Hospital
Sentara Norfolk General Hospital
Sentara Virginia Beach General Hospital
Sentara Princess Anne Hospital
Sentara Leigh Hospital
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
View 3 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors